Abou-Mrad F
Service de Neurologie, Hôpital Saint Charles, Fayadieh, Faculté des Sciences médicales, Université Libanaise, Liban.
Rev Med Brux. 2010 Sep-Oct;31(5):467-73.
In Lebanon, as in other developing countries, most of the clinical trials are achieved without considering any rule adopted in the industrialized countries, which causes serious ethical problems. This study aims to review the different Lebanese texts related to clinical trials in order to show the existing legislative frame, and to formulate suggestions that help the legislator defining better this activity. We reviewed and analyzed the Lebanese legislation related to the clinical trials especially the Lebanese law project about "therapeutic trials on human subjects" and conducted semi-directive interviews with actors from the society.
We noticed a legislative gap in this domain, highlighting the fragility of the social link in the health domain, and reverberating negatively on the physician/physician, physician/hospital, physician/industrial and industrial/hospital relationships, in addition to many gaps affecting the skills of physicians-investigators. In spite of the promising institutional effort, the national frame of clinical trials does not seem to be sufficient regarding the ignorance of applied legislative texts, the industrial promoter's weight, and the pressures. This is applied to the absence of a powerful national coordinator, the inexistence of a pharmacovigilance system or a skillful authority for the sanitary security of health products, and the confusion in the concepts of medical ethics and deontology. In conclusion were presented for achieving improvements on many levels: an objective criticism of the law project proposed in 2002 followed by a call to review its content and improve it in order to reach an instructive and applicable global legislation ; an action that can be realized only through educating adequately the investigators, and informing the large public in order to guide the governors towards a legislation allowing people in Lebanon to "live well " with complete dignity.
在黎巴嫩,与其他发展中国家一样,大多数临床试验的开展都未考虑工业化国家所采用的任何规则,这引发了严重的伦理问题。本研究旨在回顾与临床试验相关的不同黎巴嫩文本,以展示现有的立法框架,并提出有助于立法者更好地界定这一活动的建议。我们回顾并分析了黎巴嫩与临床试验相关的立法,特别是关于“人体治疗试验”的黎巴嫩法律草案,并对社会各界人士进行了半指导性访谈。
我们注意到该领域存在立法空白,凸显了卫生领域社会联系的脆弱性,对医生/医生、医生/医院、医生/企业以及企业/医院关系产生了负面影响,此外还存在许多影响医生-研究者技能的空白。尽管有颇具前景的机构努力,但由于对适用立法文本的忽视、行业推动者的影响力以及各种压力,黎巴嫩的临床试验国家框架似乎并不充分。这体现在缺乏一个强有力的国家协调机构、不存在药物警戒系统或负责卫生产品卫生安全的专业权威机构,以及医学伦理和职业道德概念的混乱。总之,为在多个层面实现改进提出了以下建议:对2002年提出的法律草案进行客观批评,随后呼吁审查其内容并加以完善,以达成一部具有指导意义且可适用的全球立法;这一行动只有通过充分教育研究者并向广大公众宣传,才能引导管理者制定一部能让黎巴嫩人民有尊严地“美好生活”的立法。